Riegler & Kirstein is a company devoted to the design of Langmuir troughs and layer-by-layer deposition (self-assembly) devices for use in the scientific field of monolayers and Langmuir-Blodgett research.
ROAR is involved in the research, development and manufacturing of nanotechnology derived particles for commercial applications. In the short to medium term, the company will concentrate in supplying nanoparticles used for forensic, immigration and sports testing applications.
Rohm and Haas Electronic Materials develops and delivers innovative material solutions and processes to the electronic and optoelectronic industries. Focused on the circuit board, semiconductor manufacturing, advanced packaging, and flat panel display industries, its products and technologies are integral elements in electronic devices around the world.
The company develops breakthrough technology based on proprietary 'Rolling Mask' lithography concept, which will enable cost-effective nanostructuring on large areas of rigid and flexible materials in conveyor or roll-to-roll modes.
Roth & Rau AG is by market share one of the world's leading suppliers of plasma process systems for the photovoltaics industry. The company also supplies components and process systems based on plasma and ion beam technology for other sectors.
Rtec Instruments specializes in tribology high tech instrument design and manufacturing. They offer products for both nanotechnology and traditional industries including tribometers, high temperature indenters, 3d profilometers, optical profilometer, atomic force microscope, mechanical property tester, film thickness measurement, stress tester.
The Russian Corporation of Nanotechnology (RCNT) was established to address the growing challenge that arises with the rapid development of new technologies in the nanoscale. The key directions of RCNT's activity are: 1) provide assistance to the state policies in the sphere of nanotechnology; 2) development of the innovative infrastructure for nanotechnologies; 3) achievement of projects aimed at creating innovative nanotechnologies and nanoindustries.
RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of serious human diseases. The company has developed novel and proprietary nanotransporters that have been shown to deliver RNAi compounds to target tissues in animal models.